RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • Why Genomics May Be in Google's DNA
    The Internet giant Google has set its sights on revolutionizing how researchers store, analyze, and share genomic data. The company recently entered into an agreement with the Broad Institute that allows it to integrate Broad’s Genomic Analysis Toolkit into Google Genomics. We spoke to David Glazer, director of engineering for Google, about its Google Genomics platform, the opportunity it sees in genomics, and what it’s doing to help researchers turn vast amounts of data into actionable information.
    24 min
  • An FDA Perspective on Rare Diseases
    The FDA Office of Orphan Products Development seeks to advance the evaluation of drugs and diagnostics to treat rare diseases. A growing toolkit of incentives has helped drive the development of new products for rare diseases, but the need remains great. We spoke to Gayatri Rao, director of the FDA’s Office of Orphan Products Development, about the rare disease landscape, how scientific developments are reshaping clinical trials and the use of biomarkers, and what the agency is doing to better incorporate patients’ perspectives into the drug review process.
    21 min
  • Helping Patients Take Control of Their Healthcare
    The world of healthcare is changing and patients today are taking a greater role in determining and coordinating their own care. Technology is playing a critical role in enabling the new patient of today and Yabidu and its online care notebook is an example of the types of tools allowing patients to become active participants in the process. We spoke to Todd Kozikowski, CEO and founder of Yabidu, about the company, how patients use its platform, and the ways technology is allowing patients to take control of their own healthcare
    21 min
  • Living Life Beyond Limits
    Bonner Paddock led an active childhood despite his physical limitations. After years of being misdiagnosed, he learned at age 11 that he had cerebral palsy, a nonprogressive brain injury that affects muscle movement and coordination. Rather than accept his physical limitations, Paddock went on to become the first person with cerebral palsy to climb Mt. Kilimanjaro, the tallest freestanding mountain in the world. He also went on to become an elite triathlete when he competed in the Kona Ironman. We spoke to Paddock about his story, his efforts to raise awareness and support for children with disabilities through his OM Foundation, and how he is working to empower children with disabilities and their families to live life beyond limits.
    18 min
  • Noah Coughlan Completes His 3,000 Mile Trek for Rare Diseases
    On February 28, World Rare Disease Day, Noah Coughlan set out on a 3,100 mile run across America from New York City to San Diego’s Ocean Beach. The goal was to raise awareness for rare diseases. On July 4, right on schedule, he finished his run entering the water in San Diego before a crowd of supporters. We spoke to Coughlan, founder of the Run4Rare Foundation, about his efforts to raise awareness for rare diseases, his recent run, and how he plans to continue his efforts.
    20 min
  • How the 21st Century Cures Act Puts Patients at the Table
    Patients, long passive participants in the drug research and development process, are playing a more active role, and the value of their input is being recognized by researchers, drugmakers, and regulators. The 21st Century Cures Act, sweeping legislation now pending in Congress, would help solidify that role by providing opportunities for patient input into the regulatory process. We spoke to Kim McCleary, managing director of FasterCures, about the legislation, why it matters, and how it will change the role of patients.
    33 min
  • Using Cell and Gene Therapies to Treat Rare Skin Diseases
    Fibrocell Science is developing cell and gene therapy to treat rare skin and connective tissue diseases. The company recently reported encouraging pre-clinical results on its gene therapy for RDEB a congenital, progressive, and debilitating genetic disorder that leads to death. The data sets the stage for Fibrocell and its partner Intrexon to advance the experimental therapy to human clinical trials. We spoke to David Pernock, chairman and CEO of Fibrocell about the company, its cell and gene therapies, and how these technologies promise to bring new approaches to treating devastating diseases.
    19 min
  • Incentives Boost Innovation in Rare Disease Therapies
    Patent filings in the area of rare diseases suggest government incentives have worked to spur innovation, according to a new report from the international intellectual property firm Marks & Clerk. The report examines patent filings in the areas of rare diseases, antibiotics, and vaccines. We spoke to Gareth Williams, partner and European patent attorney with Marks & Clerk, about the report, the role Big Pharma is playing, and some surprises on the list of top filers of rare disease related patents.
    14 min
  • Tensions Brew Between Pharma and Patient Advocacy Groups
    Disruptive changes to the healthcare landscape are creating new tensions in the traditional relationship between pharmaceutical companies and patient advocacy groups, according to the findings of a report from InVentiv Health. The report, based on interviews with nearly four dozen representatives of patient advocacy organizations, finds patient advocates expect greater transparency from their pharmaceutical partners, want to play an increased role in clinical trial design and execution, and see a role for themselves in education campaigns for patients and providers. We spoke to Heather Gartman, regional managing director of InVentiv Health, about the report, the changing dynamics between pharmaceutical companies and patient advocacy organizations, and whether the long-term health of the symbiotic relationship is in jeopardy.
    14 min
  • The Attraction of Being a Rare Disease Drug Company
    Bellus Health was originally formed around technology seen as the basis for promising therapeutics for Alzheimer’s disease, but the company also pursued rare disease opportunities as well. Despite encouraging results, the financial crisis made it difficult for the company to advance its potential Alzheimer’s therapy. With a new CEO put in place, the company overhauled its strategy, out licensed its alzheimer’s drug and embraced its identity as a rare disease drug company. We spoke to Roberto Bellini, CEO of Bellus Health, about the transformation of the company, the changing environment for orphan drugs, and why being a rare disease drug company is an attractive business model today.
    20 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.